Skip to main content
. Author manuscript; available in PMC: 2016 Feb 1.
Published in final edited form as: Am Soc Clin Oncol Educ Book. 2015:e165–e173. doi: 10.14694/EdBook_AM.2015.35.e165

Figure 2. Mechanisms of acquired resistance to crizotinib in ALK- rearranged NSCLC.

Figure 2

Resistance can be mediated by ALK target modifications, including ALK amplification and ALK kinase domain mutations and through bypass signaling pathways which circumvent the inhibited driver oncogene (the ALK fusion). Potential strategies to overcome resistance are noted in the white boxes.